Impact Capital Partners LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Impact Capital Partners LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,461 shares of the company’s stock, valued at approximately $1,128,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. DecisionMap Wealth Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $434,000. CFO4Life Group LLC boosted its holdings in Eli Lilly and Company by 3.4% during the fourth quarter. CFO4Life Group LLC now owns 1,040 shares of the company’s stock worth $803,000 after purchasing an additional 34 shares during the last quarter. Lazard Freres Gestion S.A.S. boosted its holdings in Eli Lilly and Company by 328.3% during the fourth quarter. Lazard Freres Gestion S.A.S. now owns 4,266 shares of the company’s stock worth $3,293,000 after purchasing an additional 3,270 shares during the last quarter. 1776 Wealth LLC boosted its holdings in Eli Lilly and Company by 71.1% during the fourth quarter. 1776 Wealth LLC now owns 2,024 shares of the company’s stock worth $1,563,000 after purchasing an additional 841 shares during the last quarter. Finally, Bowen Hanes & Co. Inc. boosted its holdings in Eli Lilly and Company by 2.6% during the fourth quarter. Bowen Hanes & Co. Inc. now owns 128,550 shares of the company’s stock worth $99,241,000 after purchasing an additional 3,236 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $822.26 on Thursday. The firm’s 50 day simple moving average is $829.78 and its 200 day simple moving average is $845.29. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $779.64 billion, a PE ratio of 70.22, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share buyback program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LLY. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.